Chronic myeloid leukemia (CML) is a lethal hematological malignancy defined by the presence of a BCR-ABL fusion gene originating in a hematopoietic stem cell (HSC) [1, 2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.